Outcome of Board Meeting

GlaxoSmithKline Pharmaceuticals Limited GSK House, Dr. Annie Besant Road, Worli, Mumbai -400 030 Tel No: +91 22 2495 9595 Web: www.gsk-india.com Email: askus@gsk.com 3rd August 2026 BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor, Plot No. C/1, G Block Dalal Street Bandra-Kurla Complex, Sandra (East) Mumbai -400001 Mumbai -400051 Dear Sirs, Outcome of the Board Meeting We wish to inform you that a meeting of the Board of Directors of the Company was held today, i.e. 3rd August 2026 and inter alia, transacted the following business: 1. Financial Results Pursuant to Regulation 33 read with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015, enclosed herewith are the Un-audited Standalone and Consolidated Financial Results for the first quarter ended 30th June 2026, approved by the Board of Directors of the Company at it is meeting held today along with the Limited Review Report of the Auditors. 2. Change in Management • Mr. Subesh Williams (DIN: 07786724), Non-Executive Director has stepped down from the Board from closing hours of business on 3rd August 2026. • Ms. Karine J F Natland would be appointed as Non- Executive Director on the Board w.e.f. from 3rd August 2026 or her obtaining the DIN, whichever is later. Mr. Karine J F Natland is not related to any of the existing Directors of the Company, and she is not debarred from holding the Office of Director by virtue of any order passed by SEBI or any other such authority. She does not hold any shares in the Company. Brief Profile Karine J F Natland, SVP Asia Pacific (APAC) joined GSK in 2024 to lead the product strategy for the General Medicines business, a large portfolio spanning all stages of the product lifecycle contributing to more than 30% of GSK's global sales. At the helm of General Medicines, she has led with the vision of transforming the business, reaching >1 billion patients this decade and doubling the sales of General Medicines' growth engines by 2030. She joined GSK from Organon, where she was the SVP and Regional President for Asia Pacific, including Japan and China, a region that contributed 20% of the sales to the company. Prior to Organon, she held various leadership roles across the world for Merck and Co and MSD. In Merck, she successfully led the spin-off of Organon, while in MSD she cultivated a long and successful career that included strategy and product roles as well as regional, country GM, Global Commercial and Commercial Operation positions in the USA, the Netherlands, Sub-Saharan Africa, Russia, Eastern Europe, Middle East and Africa, Emerging Markets and Norway. She holds an executive dual MBA from the Norwegian School of Management and ECSP, Paris, France, where she graduated with honors. She also holds a bachelor's degree in pharmacy, which she obtained in Norway. She is currently based in Singapore. • Re-appointment of Mr. Bhushan Akshikar (Din:09112346) as a Managing Director Mr. Bhushan Akshikar (Din:09112346) is re-appointed as a Managing Director of the Company for a term of two years w.e.f. from 1st December 2026. Mr. Bhushan Akshikar is not related to any of the_e xisting Directors of the Company, and he is not debarred from holding the Office of Director by virtue of any order passed by SEBI or any other such authority. Brief Profile Mr. Bhushan Akshikar is a seasoned business leader with a successful track record of over 30 years across local and area roles within the pharmaceutical industry. He is the Managing Director of GSK India since 2022. Joining GSK in 2011, he has spent the last 15 years in local/area commercial roles living in India, Africa and Middle East. Prior to joining GSK, Bhushan spent 15 years with Janssen, Johnson & Johnson, in various roles leading P&L for both specialty and primary care business units in local and regional positions living in India, S. Korea and Belgium. He holds a post graduate MBA in Marketing from SPJIMR and a Bachelor's Degree in Pharmaceutical Sciences from University of Pune. He is a member of the Stakeholders Relationship Committee and Corporate Social Responsibility Committee of the Company. He is the Director of Biddle Sawyer Limited. He is also the Director of Biddle Sawyer Limited. He does not hold any shares in the Company and is also not related to any Director of the Company. The Meeting of the Board of Directors of the Company commenced at 01.00 p.m. and concluded at 3.35 p.m. Thanking you, Yours faithfully For GlaxoSmithKline Pharmaceuticals Limited ~ t()C, Ajay Nadkarni Vice President - Administration, Real Estate & Company Secretary Encl: a. a. CIN: L24239MH1924PLC001151 GlaxoSmithKline Pharmaceuticals Limited Registered Office: Dr. Annie Besant Road, Mumbai -400 030 CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494 STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026 (Rs. in Lakhs) Preceeding 3 Corresponding 3 Particulars 3 months ended months ended months ended Year ended 30.06.2026 31.03.2026 30.06.2025 31.03.2026 (Unaudited) (Unaudited) (Unaudited) (Audited) (Refer note 2) Income 1 • Revenue from operations 92442 98915 80483 379020 2 Other income (Refer Note 3) 6163 3571 4376 14256 3 Total Income (1+2) 98605 102486 84859 393276 Expenses (a) Cost of materials consumed 5987 10147 12143 40007 (b) Purchases of stock-in-trade 37862 22839 23207 91044 (c) Changes in inventories of finished goods, stock-in- trade and work-in-progress (12204) 656 (6553) 1350 (d) Employee benefits expense 15904 16475 15257 60725 (e) Finance costs 97 61 42 273 (f) Depreciation and amortisation expense 1584 1317 1552 6644 (g) Other expenses 15577 14079 11354 55874 4 Total expenses 64807 65574 57002 255917 ·5 Profit before exceptional items and tax (3-4) 33798 36912 27857 137359 6 Exceptional items (credit) (Refer Note 4) - - - 264 7 Profit before tax (5+6) ·33798 36912 27857 137623 8 Tax expense (a) Current tax 8135 8724 7385 35495 (b) Deferred tax 330 694 2 946 9 Profit for the oeriod/vear (7-8) 25333 27494 20470 101182 GlaxoSmithKline Pharmaceuticals Limited Registered Office: Dr. Annie Besant Road, Mumbai -400 030 CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494 STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026 (Rs. in Lakhs) Preceeding 3 Corresponding 3 Particulars 3 months ended months ended months ended Year ended 30.06.2026 31.03.2026 30.06.2025 31.03.2026 I (Unaudited) (Unaudited) (Unaudited) (Audited) (Refer note 2) 10 Other comprehensive loss (i) Items that will not be reclassifled to profit or loss - (1827) - (998) (ii) Income tax relating to items that will not be reclassified to profit or loss - 453 - 244 11 Total comprehensive income for the period (9+10) 25333 26120 20470 100428 Paid-up equity share capital (face value per share Rs. 10) 16941 16941 16941 16941 Other equity 207177 Earnings per share (EPS) (of Rs. 10 each) Basic and diluted EPS before Exceptional items (Rs.) 14.95 16.23 12.08 59.59 Basic and diluted EPS alter Exceptional items (Rs.) 14.95 16.23 12.08 59.73 Not Annualised Notes: 1. The above results haye been reviewed by the Audit Committee and approved by.the Board of Directors at their respective meetings held on 03rd August 2026. The Statutory auditors have carried out a limited review of the standalone financial results for the quarter ended 30th June 2026. 2. The figures for the 3 months ended 31st March 2026 are the balancing figures between the audited figures in respect of full financial year and the published year to date figures upto the third quarter of the financial year ended 31st March 2026. 3. Other income for the quarter ended 30th June 2026 includes Rs. 1800 lakhs on account of dividend received from Biddle Sawyer Limited, the 100% subsidiary. 4. Exceptional items credit for the year ended 31st March 2026 of Rs. 264 lakhs is on account of pro [Showing first 8,000 characters — download PDF for full document]